Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
EXACT Therapeutics AS ( (DE:56F) ) has provided an update.
EXACT Therapeutics has announced that GE Medical Holding AB, a subsidiary of GE HealthCare Technologies, will exercise all of its 26,973,169 warrants in the company, and that together with exercises by leading shareholders and primary insiders, roughly 75% of all issued warrants are now being exercised. In connection with this warrant exercise process, the company will hold a global investor call on 11 February 2026, led by its senior management team, with a presentation to be made available on its website, underscoring heightened investor engagement and a potential strengthening of its capital base as it advances its precision oncology platform.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company listed on Euronext Growth Oslo that develops ultrasound-mediated drug activation technologies. Its proprietary agent PS101 is designed to enhance the efficacy of oncology treatments and may be combined with a broad range of therapeutic agents, with potential applications also extending to brain diseases.
Average Trading Volume: 40,207
Current Market Cap: NOK120.2M
Learn more about 56F stock on TipRanks’ Stock Analysis page.